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on HRQoL of the general population is still lacking. The aim of our study was to 
fill this GAP. Methods: A dataset with HRQoL data of a representative sample 
of the general population of most populated Italian region was matched with the 
dataset from a multicenter study conducted in the same region and time period 
to generate and validate a set of health care outcomes indicators for the major 
LDs (hepatitis B (HBV), hepatitis C (HCV), compensated cirrhosis (CC), decom-
pensated cirrhosis (DC), hepatocellular carcinoma (HCC), autoimmune hepatitis 
(AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), NAFLD/
NASH and patients listed for liver transplant (LTL)). Within both datasets, HRQoL 
data were collected using the EQ-5D-3L. Multivariate logistic and Tobit regres-
sions were then performed adjusting for possible confounders (age, sex, education 
and working status). Results: A total of 6,800 “healthy subjects” and 3,105 sub-
jects with LDs were included in the analyses. Multivariate logistic analyses showed 
that DC, HCC, and LTL had significantly (p< 0.05) higher risk to have problems in 
mobility, self-care, and usual activities compared to “healthy subjects”. AIH had 
significantly higher risk to have problems in self-care; while HCV, CC, DC, and 
NAFLD/NASH in Anxiety/depression. Similar results were obtained with the Tobit 
model performed using VAS and Utility-index. DC, HCC, AIH and LTL reported 
the highest decrease in VAS and Utility score. ConClusions: HRQoL decreased 
in advanced LDs (DC, HCC, LTL) and AIH. This study provides an actual true esti-
mate of the impact of major LDs on the patients’ HRQoL compare to the general 
population, and therefore is a key tool for decision-making in care delivery for 
liver diseases.
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objeCtives: The aims of this study were: (1) to investigate translation difficulties 
encountered during linguistic validation of the Bristol Stool Scale; (2) to discover 
whether certain items consistently posed problems across different languages; 
and (3) to analyse how solutions were reached and what types of solutions were 
appropriate. Methods: The investigation was made up of the following stages: 
(1) collation of back translation reviews of the Bristol Stool Scale for 30 European 
and Asia-Pacific languages; (2) identification of problematic words and phrases, 
based on written discussion between lead translators and project managers; (3) 
investigation of patterns that became apparent across different languages; (4) 
review of methods used to overcome the translation difficulties. Results: For 
more than a third of the languages reviewed (2 European and 9 Asia-Pacific, includ-
ing 7 Indian), difficulties were experienced when attempting to translate certain 
items word-for-word. The majority of these difficulties centred on the food-related 
similes used in the scale to describe the different stool types. In all of the Indian 
languages in this study, alternative food-related similes were deemed necessary 
(e. g. ‘banana’ replacing ‘sausage’) in order to ensure that the wording was cultur-
ally relevant. Of the other languages, Thai and Romanian preferred similes that 
did not relate to food (‘bullets’ and ‘beads/little round bits’ respectively, instead of 
‘nuts’), while for Singapore Chinese and Polish it was decided to remove certain 
similes altogether (‘like nuts’/‘like a sausage’). ConClusions: Certain items in 
the Bristol Stool Scale, in particular the two food-related similes, cause transla-
tion difficulties for some languages. For such items, it may not be appropriate to 
produce a word-for-word translation. In these cases, alternative solutions must 
be sought, taking into account cultural considerations, in order to achieve con-
ceptual equivalence.
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objeCtives: To describe and compare self-reported health-related quality of 
life (HRQL) in HCV Genotype-1 infected patients with and without comorbid 
conditions (e. g. depression, hypertension, obesity, arthritis, anemia and dia-
betes). Methods: A Cross-sectional survey of physicians and their consulting 
patients was conducted from October 2012 to January 2013 as part of the Adelphi 
Real World Hepatitis C Disease Specific Programme. Overall, 348 patients from USA 
and France (231 with comorbidities and 117 without comorbidities) completed an 
EQ5D-3L and/or a Multidimensional-Assessment-of-Fatigue (MAF) scale. HRQL was 
evaluated by estimating EQ5D health-state-index (EQ5D-HSI), Visual-Analogue-
Scale (EQ5D-VAS) score, Domain-dimension score and MAF Global-Fatigue-Index 
(MAF-GFI). Further analysis compared HRQL reported by patients with comorbidi-
ties who completed treatment for HCV and were cured versus those who were 
not cured. Results: HRQL reported by untreated patients were better for those 
without comorbidities than those with comorbidities. For three of the five EQ5D 
domains, more patients without comorbidities versus patients with comorbidities 
reported no problems performing usual activities (85% versus 49%, p< 0.001), no 
pain or discomfort (70% versus 33%, p< 0.001) and not being anxious/depressed 
(67% versus 37%, p= 0.004). The corresponding mean HQRL estimates were EQ5D-
HSI 0.89 vs 0.77, p= 0.001; EQ5D-VAS 79 vs. 69, p= 0.014 and MAF-GFI 11 vs. 19, 
p= 0.016 for patients without comorbidities versus those with comorbidities. 
Among treated patients with comorbidities, those cured had significantly higher 
HRQL than those not cured (EQ5D-HSI 0.84 versus 0.67, p= 0.008, EQ5D-VAS 74 
vs. 57, p= 0.003 and MAF-GFI 18 versus 32, p< 0.001). ConClusions: The results 
from this study suggest that patients with comorbidities have a poorer HRQL than 
patients without comorbidities, and that the treatment and cure of HCV in these 
patients is associated with higher HRQL compared with treatment and no cure. 
This implies that treatment and subsequent cure of HCV genotype 1 patients with 
comorbidities may help improve their HRQL.
caregivers. Results: 468 children and caregivers were included in this study. Mean 
children’s age was 1.77 years. The caregivers rated the mean child’s utility and 
themselves as 0.604 (95%CI: 0.592, 0.615) and 0.618 (95%CI: 0.606, 0.629), respectively. 
Mainly domains of diarrheal children were affected as pain/discomfort and anxiety/
depression similarly to their caregivers. On multivariate regression analysis, factors 
which affected the children’s utility significantly were Vesikari score, child’s age and 
child’s gender. Next, reduced QoL of their caregivers related to caregiver’s gender and 
Vesikari score. ConClusions: Diarrhea had an impact on quality of life of children 
and their caregivers. It appeared that QoL of children with diarrhea was impacted 
worse in girls, those with high severity score and was associated with age. In addi-
tion, the diarrheal severity and female gender reduced the impact of diarrhea on 
QoL of caregivers. These results can be useful to evaluate the cost-effectiveness of 
vaccines against diarrhea such as rotavirus vaccines.
PGI36
hoW does non-malIGnanT oPIoId InduCed ConsTIPaTIon (oIC) ImPaCT 
healTh sTaTe uTIlITy?
Lawson R.1, Marsh K.2, Altincatal A.3, King F.4
1AstraZeneca, Cheshire, UK, 2Evidera, London, UK, 3Evidera, Lexington, MA, USA, 4AstraZeneca, 
Gaithersberg, MD, USA
objeCtives: Little is known about the impact of OIC and treatments for OIC on 
health state utility. Studies often focus on collecting data on changes in OIC status. 
The objective of this paper is to examine if the utility impact of treatment is driven 
by change in OIC status, and what the magnitude of the change in utility associ-
ated with changes in OIC status is. Methods: 1352 patients with non-malignant 
OIC were allocated to one of two, phase III, 12 week randomised controlled trials 
to study naloxegol. These trials were pooled and prospective analyses on these 
data were undertaken. Both trials collected the three level EQ-5D at baseline, 
week 4 and week 12. EQ-5D scores were converted into estimates of utility using a 
tariff generated based on UK general population preferences. A repeated measure 
mixed model (RMMM) regression analysis was conducted to identify the impact 
of the following factors on utility: age, gender, race, BMI, duration of opioid use, 
treatment (naloxegol 12.5mg, 25mg or placebo), baseline utility and OIC status (OIC 
or non-OIC). Results: Baseline utility across all patients was 0.559. The regres-
sion demonstrated that baseline utility score (β = -0.532, SE= 0.023) and OIC status 
(β = 0.032, SE= 0.012) were the only significant predictors of change in utility score 
(p< 0.0001and p= 0.008 respectively). Further univariate analyses examined the 
effect of OIC status in patient subgroups that had different experiences of laxative 
treatment. OIC status had an increased and meaningful impact on patients who 
had previously responded inadequately to laxatives. ConClusions: OIC status 
is a significant factor on the impact of treatment on patient’s utility. Furthermore 
the impact of OIC status is increased in patients who had previously responded 
inadequately to laxatives.
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objeCtives: A recent double-blind, placebo-controlled clinical study with lubipros-
tone in opioid-induced constipation (OIC), OBD-1033, included the EQ-5D generic 
quality-of-life instrument, and the PAC-QOL, a constipation-specific disease meas-
ure. This study calculated utility values for patients with OIC using the direct EQ-5D 
responses, and compared the resulting utilities to those calculated from a published 
mapping formula between the PAC-QOL and EQ-5D that was derived in chronic idi-
opathic constipation. Methods: EQ-5D responses from OBD-1033 were converted 
to utilities using the EQ-5D UK value set. These were compared with utilities gener-
ated with the published mapping algorithm. Following this step, an attempt was 
made to map the PAC-QOL to the EQ-5D in OIC. The root mean squared error (RMSE), 
adjusted R2, and predicted/observed plots were used to assess the quality of map-
pings. Results: Patients in OBD-1033 had low utility values at baseline: mean= 0.45 
(Standard Deviation 0.33, n= 439). Using the published algorithm, the predicted mean 
utility was much higher: 0.74. This led to a high RMSE (0.43), indicating a poor fit 
to the data. Replicating the mapping using OBD-1033 PAC-QOL and EQ-5D data 
showed the PAC-QOL, although correlated with the EQ-5D, had a poor predictive 
value (RMSE= 0.31; R2< 0.10). High utilities were underestimated and low utilities 
overestimated. ConClusions: Mapping algorithms are a vital tool for generating 
utility values when none are available. However, the relationship derived between 
instruments should be assessed cautiously. Mappings with the same instruments 
may not be reliable if crossing disease areas – even if the symptoms experienced 
by patients appear similar. Data show patients in OBD-1033 entered the study with 
poorer health status than those in the chronic constipation mapping (utility of 
0.45 vs 0.81), likely due to comorbid conditions (the reason for opioid prescribing). 
This led to a different relationship between the PAC-QOL and EQ-5D, compared to 
the previous estimate.
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objeCtives: The impact of liver diseases (LDs) on health-related quality of life 
(HRQoL) is an important aspect to understand the burden of these conditions 
and improve their management. A well characterized impact of the major LDs 
